Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2012 Nov 18;137(1):93–107. doi: 10.1007/s10549-012-2332-x

Fig. 8. NF-κB1 expression analysis in xenograft tumors treated with LBH589.

Fig. 8

(A) Tumors from LBH589-treated or control mice (four mice/group) with exemestane-resistant MCF-7aro tumors were harvested 48 hours after mice received a single injection of LBH589. Real time PCR was performed to quantify the levels of NFκB mRNA in tumors. (B) Real time PCR analysis of levels of NF-κB mRNA present in tumors at the end of experiment. n = 7 mice/group. (C) LBH589 decreased cell proliferation in the parental cell line, MCF7aro, in a dose-dependent manner but not in long-term exemestane-treated LTET cells established from MCF-7aro tumors from mice treated with exemestane. The LTET and MCF-7aro cells were treated with the indicated concentrations of exemestane or LBH589 for 6 days and proliferation analyzed by MTT assay. (D) Baseline NF-κB1 mRNA expression was significantly increased in LTET cells as compared to the parental MCF7aro cells, as determined by real-time PCR analysis. *, p < 0.05; **, p < 0.01.